The biotechnology industry has been mounting a powerful rally, emerging as a standout performer in the equity market, which has otherwise been dominated by technology giants of late. Over the past ...

XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has ...

XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has ...

Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing ...

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Nasdaq has long been the home for biotech companies, and this past January, National Biotechnology Month proved no different. The sector was active with five healthcare companies raising $800 million ...

UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...

Grogan served as assistant to President Trump and director of the Domestic Policy Council 2019-2020. On April 15, President Trump issued an awaited executive order on drug pricing, kicking off a new ...

This is not possible without a steadfast commitment from our partners in the federal government and private industry. It’s ...

North Carolina’s life sciences industry has grown to include 860 companies statewide that employ 76,000 North Carolinians, ...